VIR
Vir Biotechnology Inc
11.20$
-1.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
Vir Biotechnology Inc (VIR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -9.1 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -15 | -15 | -35 | -30 | -29 | -24 | -37 | -39 | -48 | -11 | -50 | -82 | -90 | 140 | -106 | 7.7 | 550 | 960 | 118 | 35 | -126 | -389 | -156 | -108 | -109 | -78 | -171 | -88 | -78 | -120 | -168 | -26 | -132 | -9.1 | -335 | |
| 0.3 | 0.3 | 0.7 | 0.9 | 1.0 | 1.1 | 1.2 | 1.2 | 1.3 | 1.4 | 1.4 | 2.2 | 1.4 | 2.9 | 3.0 | 3.2 | 1.6 | 3.8 | 3.9 | 4.2 | 7.8 | 7.0 | 6.4 | 4.5 | 4.5 | 4.3 | 2.9 | 2.9 | 2.9 | 9.5 | 3.0 | 2.9 | 2.8 | 5.6 | 14 | |
| 1.3 | 1.3 | 1.4 | 1.0 | 2.5 | 1.4 | 2.2 | 2.7 | 3.0 | 5.8 | 8.6 | 10 | 15 | 21 | 23 | 24 | 25 | 27 | 25 | 25 | 25 | 31 | 27 | 28 | 24 | 22 | 17 | 16 | 14 | 12 | 11 | 23 | 12 | 24 | 70 | |
| 2.9 | 2.9 | 1.1 | – | 2.9 | 6.5 | 6.5 | 22 | 28 | 21 | 27 | -3.7 | 15 | 21 | -141 | 92 | 121 | 39 | 38 | 5.0 | 39 | 48 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 2.3 | 2.3 | -3.0 | -3.5 | -4.7 | 7.6 | 3.6 | 1.7 | -0.8 | -1.9 | 6.2 | 26 | 16 | 57 | -90 | -611 | 3.9 | 587 | -55 | 130 | 11 | -253 | -30 | -33 | -82 | -2.4 | 17 | -17 | 26 | -25 | -21 | -2.8 | -23 | 0.8 | -45 | |
| 2.8 | 2.8 | 1.5 | 2.8 | 3.5 | 2.7 | 1.3 | 1.6 | 1.3 | 1.3 | 1.5 | 2.4 | 0.7 | 2.1 | 6.0 | 13 | 16 | 21 | 19 | 13 | 6.9 | 9.5 | 3.7 | 1.5 | 1.9 | 0.7 | 2.4 | 2.4 | 1.6 | 2.5 | 0.3 | 4.5 | 0.4 | 0.4 | 5.6 | |
| -47 | -47 | 18 | 16 | -274 | 44 | 47 | -74 | 104 | 11 | -185 | 61 | 88 | 75 | 74 | -378 | -105 | -272 | -663 | -153 | 98 | 230 | -59 | -105 | 28 | 212 | 119 | 141 | 127 | 56 | 40 | 87 | 12 | -185 | -46 | |
| 0.0 | 0.0 | – | – | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | 2.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.0 | 15 | 15 | 317 | 318 | 318 | 0.0 | 0.1 | – | – | – | 88 | 3.6 | 3.7 | 2.3 | 0.5 | 3.1 | 2.0 | 3.2 | 2.4 | 3.2 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.0 | 4.4 | – | 1.2 | 1.2 | 1.2 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | – | – | – | – | – | 0.0 | – | 0.0 | – | – | – | – | – | – | |
| 6.2 | 6.2 | 2.2 | 10 | 317 | 0.0 | 1.7 | 130 | 0.1 | 205 | 324 | -0.3 | 88 | 3.5 | 3.6 | 5.7 | 28 | 3.1 | 2.0 | 2.0 | 2.2 | 3.2 | 0.3 | 1.7 | 0.2 | 2.9 | 0.0 | 1.3 | 0.6 | 2.0 | 0.1 | 1.0 | 163 | 241 | 405 | |
| -56 | -33 | -14 | -3.0 | 14 | 20 | 12 | 13 | 56 | 205 | 89 | -27 | 86 | 219 | -28 | -364 | 472 | 692 | -542 | -115 | -25 | -156 | -215 | -210 | -81 | 137 | -53 | 54 | 49 | -62 | -127 | 62 | 42 | 47 | 23 | |
| -18 | -18 | -36 | -32 | -33 | -27 | -38 | -40 | -50 | -12 | -51 | -84 | -90 | 138 | -112 | -5.4 | 534 | 940 | 99 | 23 | -133 | -399 | -160 | -109 | -111 | -79 | -174 | -90 | -80 | -123 | -168 | -21 | -133 | -9.5 | -332 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.